This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01650259
First received: July 24, 2012
Last updated: August 25, 2017
Last verified: August 2017
History of Changes
July 24, 2012
August 25, 2017
July 2012
October 2017   (Final data collection date for primary outcome measure)
Incidence of adverse drug reactions (ADRs) [ Time Frame: up to 156 weeks ]
Not Provided
Complete list of historical versions of study NCT01650259 on ClinicalTrials.gov Archive Site
The change from the baseline in HbA1c to the last-observation on treatment [ Time Frame: up to 156 weeks ]
  • The change between baseline and observation period in HbA1c [ Time Frame: up to 156 weeks ]
  • Incidence of adverse drug reactions (ADRs) [ Time Frame: up to 156 weeks ]
  • Incidence of serious adverse events (SAEs) [ Time Frame: up to 156 weeks ]
  • Incidence of cardiovascular events [ Time Frame: up to 156 weeks ]
Not Provided
Not Provided
 
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus starting Trazenta® Tablets or any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug).
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
3300
Diabetes Mellitus, Type 2
  • Drug: OAD
    OAD except Trazenta tablets
  • Drug: Trazenta
    Linagliptin
  • Oral antidiabetic drug (OAD)
    Intervention: Drug: OAD
  • Trazenta
    Intervention: Drug: Trazenta
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4554
October 2017
October 2017   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Male and female patients with type 2 Diabetes Mellitus who have never been treated with Trazenta tablets / Linagliptin (monotherapy) before enrollment. (Trazenta group)
  • Patients with type 2 Diabetes Mellitus starting any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug (OAD)) except Trazenta tablets. (OAD group)

Exclusion criteria:
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01650259
1218.95
Not Provided
Not Provided
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Eli Lilly and Company
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP